Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_2
2
50%
Ph phase_1
2
50%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(2)

Detailed Status

Completed2
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (50.0%)
Phase 22 (50.0%)

Trials by Status

completed250%
withdrawn250%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects

NCT04334460
withdrawnphase_2

Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF

NCT04244825
withdrawnphase_1

Healthy Volunteer Study Comparing Tablet and Capsule Formulations

NCT04001998
completedphase_1

First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis

NCT03559166

Clinical Trials (4)

Showing 4 of 4 trials
NCT04334460Phase 2

Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects

Completed
NCT04244825Phase 2

Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF

Withdrawn
NCT04001998Phase 1

Healthy Volunteer Study Comparing Tablet and Capsule Formulations

Withdrawn
NCT03559166Phase 1

First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4